NASDAQ:TTOO - Nasdaq - US89853L3024 - Common Stock - Currency: USD
0.134
-0.06 (-31.07%)
The current stock price of TTOO is 0.134 USD. In the past month the price decreased by -58.13%. In the past year, price decreased by -97.54%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
T2 BIOSYSTEMS INC
101 Hartwell Ave
Lexington MASSACHUSETTS 02421 US
CEO: John Sperzel
Employees: 113
Company Website: https://www.t2biosystems.com/
Investor Relations: http://investors.t2biosystems.com/
Phone: 17814571200
The current stock price of TTOO is 0.134 USD. The price decreased by -31.07% in the last trading session.
The exchange symbol of T2 BIOSYSTEMS INC is TTOO and it is listed on the Nasdaq exchange.
TTOO stock is listed on the Nasdaq exchange.
6 analysts have analysed TTOO and the average price target is 5.1 USD. This implies a price increase of 3705.97% is expected in the next year compared to the current price of 0.134. Check the T2 BIOSYSTEMS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
T2 BIOSYSTEMS INC (TTOO) has a market capitalization of 3.76M USD. This makes TTOO a Nano Cap stock.
T2 BIOSYSTEMS INC (TTOO) currently has 113 employees.
The Revenue of T2 BIOSYSTEMS INC (TTOO) is expected to grow by 51.43% in the next year. Check the estimates tab for more information on the TTOO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TTOO does not pay a dividend.
T2 BIOSYSTEMS INC (TTOO) will report earnings on 2025-05-05.
T2 BIOSYSTEMS INC (TTOO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.82).
The outstanding short interest for T2 BIOSYSTEMS INC (TTOO) is 5.43% of its float. Check the ownership tab for more information on the TTOO short interest.
ChartMill assigns a fundamental rating of 1 / 10 to TTOO. Both the profitability and financial health of TTOO have multiple concerns.
Over the last trailing twelve months TTOO reported a non-GAAP Earnings per Share(EPS) of -7.82. The EPS increased by 97.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -237.55% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to TTOO. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 83.26% and a revenue growth 51.43% for TTOO